Literature DB >> 21148491

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

Tiffany G Sheu1, Alicia M Fry, Rebecca J Garten, Varough M Deyde, Thein Shwe, Lesley Bullion, Patrick J Peebles, Yan Li, Alexander I Klimov, Larisa V Gubareva.   

Abstract

Two distinct genetic clades of seasonal influenza A(H1N1) viruses have cocirculated in the recent seasons: clade 2B oseltamivir-resistant and adamantane-susceptible viruses, and clade 2C viruses that are resistant to adamantanes and susceptible to oseltamivir. We tested seasonal influenza A(H1N1) viruses collected in 2008-2010 from the United States and globally for resistance to antivirals approved by the Food and Drug Administration. We report 28 viruses with both adamantane and oseltamivir (dual) resistance from 5 countries belonging to 4 distinct genotypes. Because of limited options for antiviral treatment, emergence of dual-resistant influenza viruses poses a public health concern, and their circulation needs to be closely monitored.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21148491      PMCID： PMC3086447          DOI： 10.1093/infdis/jiq005

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  16 in total

1.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.

Authors:  Koichiro Tamura; Joel Dudley; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2007-05-07       Impact factor: 16.240

2.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Authors:  A Lackenby; O Hungnes; S G Dudman; A Meijer; W J Paget; A J Hay; M C Zambon
Journal:  Euro Surveill       Date:  2008-01-31

3.  Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.

Authors:  I G Barr; A C Hurt; P Iannello; C Tomasov; N Deed; N Komadina
Journal:  Antiviral Res       Date:  2006-08-28       Impact factor: 5.970

4.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

5.  Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.

Authors:  I G Barr; Y M Deng; P Iannello; A C Hurt; N Komadina
Journal:  Antiviral Res       Date:  2008-07-09       Impact factor: 5.970

6.  Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.

Authors:  Aeron C Hurt; Joanne Ernest; Yi-Mo Deng; Pina Iannello; Terry G Besselaar; Chris Birch; Philippe Buchy; Malinee Chittaganpitch; Shu-Chun Chiu; Dominic Dwyer; Aurélie Guigon; Bruce Harrower; Ip Peng Kei; Tuckweng Kok; Cui Lin; Ken McPhie; Apandi Mohd; Remigio Olveda; Tony Panayotou; William Rawlinson; Lesley Scott; David Smith; Holly D'Souza; Naomi Komadina; Robert Shaw; Anne Kelso; Ian G Barr
Journal:  Antiviral Res       Date:  2009-03-24       Impact factor: 5.970

Review 7.  The potential impact of neuraminidase inhibitor resistant influenza.

Authors:  Angie Lackenby; Catherine I Thompson; Jane Democratis
Journal:  Curr Opin Infect Dis       Date:  2008-12       Impact factor: 4.915

8.  Molecular evolution of human influenza A viruses in a local area during eight influenza epidemics from 2000 to 2007.

Authors:  Hassan Zaraket; Reiko Saito; Isamu Sato; Yasushi Suzuki; Danjuan Li; Clyde Dapat; Isolde Caperig-Dapat; Taeko Oguma; Asami Sasaki; Hiroshi Suzuki
Journal:  Arch Virol       Date:  2009-01-20       Impact factor: 2.574

9.  Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08.

Authors:  Siri H Hauge; Hege S Blix; Katrine Borgen; Olav Hungnes; Susanne G Dudman; Preben Aavitsland
Journal:  Virol J       Date:  2009-05-12       Impact factor: 4.099

10.  Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States.

Authors:  Martha I Nelson; Laurel Edelman; David J Spiro; Alex R Boyne; Jayati Bera; Rebecca Halpin; Naomi Sengamalay; Elodie Ghedin; Mark A Miller; Lone Simonsen; Cecile Viboud; Edward C Holmes
Journal:  PLoS Pathog       Date:  2008-08-22       Impact factor: 6.823
View more
  62 in total

1.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

3.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

4.  Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.

Authors:  Jizhou Wang; Chunlong Ma; Jun Wang; Hyunil Jo; Belgin Canturk; Giacomo Fiorin; Lawrence H Pinto; Robert A Lamb; Michael L Klein; William F DeGrado
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

5.  Virtual screening of potential inhibitors from TCM for the CPSF30 binding site on the NS1A protein of influenza A virus.

Authors:  Haixin Ai; Li Zhang; Alan K Chang; Hongyun Wei; Yuchen Che; Hongsheng Liu
Journal:  J Mol Model       Date:  2014-02-23       Impact factor: 1.810

6.  Combination antiviral therapy for influenza: predictions from modeling of human infections.

Authors:  Alan S Perelson; Libin Rong; Frederick G Hayden
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 7.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

8.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.

Authors:  Rameshwar U Kadam; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-21       Impact factor: 11.205

9.  Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.

Authors:  Yanmei Hu; Yuanxiang Wang; Fang Li; Chunlong Ma; Jun Wang
Journal:  Eur J Med Chem       Date:  2017-04-20       Impact factor: 6.514

10.  Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase.

Authors:  Gema L Ramírez-Salinas; J García-Machorro; Miguel Quiliano; Mirko Zimic; Verónica Briz; Saul Rojas-Hernández; J Correa-Basurto
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.